- Home
- PHT vs IMMP Comparison
PHT vs IMMP Comparison
Compare PHT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- IMMP
- Stock Information
- Founded
- PHT 2002
- IMMP 1987
- Country
- PHT United States
- IMMP Australia
- Employees
- PHT N/A
- IMMP N/A
- Industry
- PHT Investment Managers
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- IMMP Health Care
- Exchange
- PHT Nasdaq
- IMMP Nasdaq
- Market Cap
- PHT 237.1M
- IMMP 244.5M
- IPO Year
- PHT N/A
- IMMP N/A
- Fundamental
- Price
- PHT $8.06
- IMMP $1.71
- Analyst Decision
- PHT
- IMMP Buy
- Analyst Count
- PHT 0
- IMMP 1
- Target Price
- PHT N/A
- IMMP $7.00
- AVG Volume (30 Days)
- PHT 85.5K
- IMMP 83.4K
- Earning Date
- PHT 01-01-0001
- IMMP 02-27-2025
- Dividend Yield
- PHT 8.76%
- IMMP N/A
- EPS Growth
- PHT N/A
- IMMP N/A
- EPS
- PHT 0.98
- IMMP N/A
- Revenue
- PHT N/A
- IMMP $3,019,249.00
- Revenue This Year
- PHT N/A
- IMMP $50.37
- Revenue Next Year
- PHT N/A
- IMMP N/A
- P/E Ratio
- PHT $7.71
- IMMP N/A
- Revenue Growth
- PHT N/A
- IMMP 24.11
- 52 Week Low
- PHT $6.41
- IMMP $1.32
- 52 Week High
- PHT $7.60
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- PHT 53.87
- IMMP 49.36
- Support Level
- PHT $8.09
- IMMP $1.60
- Resistance Level
- PHT $8.16
- IMMP $1.72
- Average True Range (ATR)
- PHT 0.05
- IMMP 0.06
- MACD
- PHT -0.01
- IMMP 0.01
- Stochastic Oscillator
- PHT 28.57
- IMMP 62.14
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.